Steven L. Hoerter - 17 Oct 2025 Form 4 Insider Report for MBX Biosciences, Inc. (MBX)

Reporting relationship: Director
Issuer ticker: MBX
Reported as of: 17 Oct 2025
Net transaction value: +$264,984
SEC form: 4
Accepted by SEC: 20 Oct 2025, 16:44:37 UTC
Prior SEC filing: 20 Jun 2025
Next SEC filing: 22 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Richard Bartram, attorney-in-fact

Key filing fact

Steven L. Hoerter filed Form 4 for MBX Biosciences, Inc. (MBX) on 20 Oct 2025.

Key facts

This page summarizes Steven L. Hoerter's Form 4 filing for MBX Biosciences, Inc. (MBX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 20 Oct 2025, 16:44.

Change

Previous filing in this sequence was filed on 20 Jun 2025.
Current net transaction value: +$264,984.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001533451 Primary reporting owner

Hoerter Steven L.

Relationship: Director
Address: C/O MBX BIOSCIENCES INC., 11711 N. MERIDIAN STREET, SUITE 300, CARMEL
Signature: /s/ Richard Bartram, attorney-in-fact
Signature date: 20 Oct 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MBX transaction

Common Stock

Purchase

Transaction value: $264,984
Shares: +20,000
Change %
Price: $13.25
Shares after: 20,000
Date: 17 Oct 2025
Ownership: By Trust
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Shares held by the Steven L Hoerter Revocable Trust dated November 2, 2018, of which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.